Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ASHOK PATEL

NPI
1093809576
CMS profile
276954
Location
TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$14,560.76

55 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Otsuka America Pharmaceutical, Inc. $13,844.54 20
ABBVIE INC. $291.15 23
ACADIA Pharmaceuticals Inc $244.82 2
Takeda Pharmaceuticals U.S.A., Inc. $88.39 6
Eisai Inc. $56.75 2
Lilly USA, LLC $19.84 1
UCB, Inc. $15.27 1

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ASHOK PATEL

NPI 1093809576 · CMS profile ID 276954

TOMS RIVER, NJ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093809576?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093809576?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). ASHOK PATEL, NPI 1093809576, CMS profile ID 276954. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093809576?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
ASHOK PATEL, NPI 1093809576, CMS profile ID 276954, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–55 of 55 matching records. This page contains 5 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1093809576?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

55 matching records · $14,560.76 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 55 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–55 of 55.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $19.8403/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031283387 CMS
UCB, Inc. $15.2702/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021959473 CMS
ABBVIE INC. $16.4502/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083377 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.4701/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1055530685 CMS
ABBVIE INC. $10.9401/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998083375 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,320.42 66
PY2020 $2,969.84 33
PY2021 $7,553.27 35
PY2022 $6,054.38 18
PY2023 $14,560.76 55
PY2024 $22,723.92 31
PY2025 $6,910.62 19

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,752.51 11
PY2025 Principal investigator $1,229,009.00 130
PY2024 Principal investigator $3,194,861.98 28
PY2023 Recipient $355.00 1
PY2023 Principal investigator $1,914,939.19 59
PY2022 Recipient $1,248.00 4
PY2022 Principal investigator $1,105,512.02 75
PY2021 Recipient $13,374.00 3
PY2021 Principal investigator $1,695,784.21 81
PY2020 Recipient $6,288.97 21
PY2020 Principal investigator $1,118,610.73 104
PY2019 Recipient $18,854.85 12
PY2019 Principal investigator $1,138,230.38 171

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

141 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,402.52 12/31/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Fixed-dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202532983
Principal investigator 1 ABBVIE INC. $1,222.42 12/31/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Multicenter, Open-label Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202532985
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202532987
Principal investigator 1 ABBVIE INC. $2,818.88 12/31/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose Study to Evaluate the Efficacy, Safety, and Tolerability of ABBV-932 as an Adjunct to Antidepressant Therapies in the Treatment of Subjects with Generalized Anxiety Disorder who have had an Inadequate Response to Antidepressant Therapies No dispute reported 06/30/2026 1202532989
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,351.00 12/23/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242369651
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $519.00 12/23/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242369653
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,997.00 12/23/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242369655
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $519.00 12/23/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242369657
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $4,495.00 12/23/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242369659
Principal investigator 1 Eisai Inc. $40,541.90 12/17/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557723
Principal investigator 1 ABBVIE INC. $3,535.00 12/04/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528430
Principal investigator 1 ABBVIE INC. $16,005.60 12/04/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202528436
Principal investigator 1 ABBVIE INC. $43,301.77 12/04/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202528438
Principal investigator 1 ABBVIE INC. $19,500.00 12/04/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of ABBV-932 in Subjects with Depressive Episodes Associated with Bipolar I or II Disorder No dispute reported 06/30/2026 1202528454
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,863.00 11/25/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242367687
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,863.00 11/25/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242367689
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $5,863.00 11/25/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242367691
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,286.00 11/25/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242367693
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,804.00 11/25/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242367695
Principal investigator 1 Eisai Inc. $9,898.20 11/20/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557721
Principal investigator 1 ABBVIE INC. $58,425.84 11/05/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202522555
Principal investigator 1 ABBVIE INC. $22,400.00 11/05/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522557
Principal investigator 1 ABBVIE INC. $11,951.40 11/05/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202522559
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $217.00 11/03/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242365255
Principal investigator 1 Eisai Inc. $8,247.60 10/24/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557719
Principal investigator 1 ABBVIE INC. $439.93 10/20/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202517447
Principal investigator 1 ABBVIE INC. $5,650.00 10/09/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202516245
Principal investigator 1 ABBVIE INC. $5,235.85 10/09/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202516247
Principal investigator 1 ABBVIE INC. $35,490.00 10/09/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202516249
Principal investigator 1 ABBVIE INC. $5,274.60 10/09/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202516417
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,216.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362441
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,216.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362443
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $144.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362445
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $49.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362447
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $105.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362449
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $162.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362451
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $6,518.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362453
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $3,206.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362455
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $7,342.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362457
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $217.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362459
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $217.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362461
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $49.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362463
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $105.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362465
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $105.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362467
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $162.00 10/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-201 No dispute reported 06/30/2026 1242362469
Principal investigator 1 ABBVIE INC. $4,350.00 09/23/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202511892
Principal investigator 1 ABBVIE INC. $5,232.00 09/22/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202511746
Principal investigator 1 Eisai Inc. $8,247.60 09/17/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557717
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $13,624.84 08/21/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795605
Principal investigator 1 Eisai Inc. $3,252.60 08/13/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557711
Principal investigator 1 ABBVIE INC. $5,124.00 08/06/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202503151
Principal investigator 1 ABBVIE INC. $5,566.40 08/06/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202503153
Principal investigator 1 Eisai Inc. $4,898.70 07/23/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557713
Principal investigator 1 Eisai Inc. $5,997.60 07/09/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557715
Principal investigator 1 ABBVIE INC. $12,110.00 07/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202494273
Principal investigator 1 ABBVIE INC. $12,038.80 07/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202494279
Principal investigator 1 ABBVIE INC. $12,000.00 07/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202495137
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,500.00 07/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795603
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $380.72 06/24/2025 Non-covered Recipient Entity
Biology Behavioral Health
Phase III Safety and Efficacy of KarXT in Psychosis Associated with AD (ADEPT 4): 2 of 2 Acute Studies No dispute reported 06/30/2026 1235998660
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $699.65 06/23/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795601
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $1,329.67 06/18/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795595
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $114.65 06/18/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795597
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $5,831.97 06/18/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795599
Principal investigator 1 ABBVIE INC. $22,960.00 06/03/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202487663
Principal investigator 1 ABBVIE INC. $8,752.40 06/03/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202487665
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $37,564.00 06/02/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795593
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664322
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 06/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664324
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664326
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 06/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664328
Principal investigator 1 ABBVIE INC. $4,400.00 05/29/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202487011
Principal investigator 1 ABBVIE INC. $4,400.00 05/29/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202487013
Principal investigator 1 ABBVIE INC. $6,580.00 05/07/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483545
Principal investigator 1 ABBVIE INC. $17,224.00 05/07/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202483547
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 05/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664312
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664314
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664316
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 05/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664318
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 05/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664320
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $57,656.00 04/28/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795591
Recipient ABBVIE INC. $1,824.27 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400444
Recipient ABBVIE INC. $24.99 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400448
Recipient ABBVIE INC. $59.98 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400451
Recipient ABBVIE INC. $49.99 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400454
Recipient ABBVIE INC. $24.99 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400459
Recipient ABBVIE INC. $86.10 04/10/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400463
Recipient ABBVIE INC. $149.99 04/09/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400425
Recipient ABBVIE INC. $303.97 04/09/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400427
Recipient ABBVIE INC. $20.00 04/09/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400432
Recipient ABBVIE INC. $124.90 04/09/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400436
Recipient ABBVIE INC. $83.33 04/09/2025 Covered Recipient Physician Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder No dispute reported 06/30/2026 1202400440
Principal investigator 1 ABBVIE INC. $9,241.00 04/03/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202471083
Principal investigator 1 ABBVIE INC. $23,380.00 04/03/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202472369
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $10,000.00 04/02/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ITI-1284-101 No dispute reported 06/30/2026 1242338949
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664300
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 04/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664302
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664304
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 04/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664306
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 04/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664308
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 04/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664310
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $131,361.00 03/28/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795589
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,594.95 03/25/2025 Non-covered Recipient Entity
Biology Behavioral Health
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1235998658
Principal investigator 1 Eisai Inc. $1,626.30 03/21/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557709
Principal investigator 1 Eisai Inc. $6.72 03/17/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY DBA ST LOUIS CLINICAL TRIALS
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558680
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $622.50 03/13/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795585
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $622.50 03/13/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795587
Principal investigator 1 ABBVIE INC. $6,580.00 03/07/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202460833
Principal investigator 1 ABBVIE INC. $12,769.00 03/07/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
M23-894 - Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder (CANTO) No dispute reported 06/30/2026 1202460837
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664272
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 03/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664274
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664276
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 03/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664278
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 03/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664280
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 03/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664282
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $16,859.00 03/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795583
Principal investigator 1 Boehringer Ingelheim International GmbH $979.02 02/25/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664284
Principal investigator 1 Boehringer Ingelheim International GmbH $268.18 02/25/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664292
Principal investigator 1 Boehringer Ingelheim International GmbH $1,058.50 02/25/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664294
Principal investigator 1 Boehringer Ingelheim International GmbH $10.64 02/25/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664296
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $298,960.00 02/10/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795581
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $17,000.00 02/07/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220795579
Principal investigator 1 ABBVIE INC. $10,500.00 02/06/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202449891
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664258
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 02/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664260
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664262
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 02/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664264
Principal investigator 1 Boehringer Ingelheim International GmbH $86.00 02/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664266
Principal investigator 1 Boehringer Ingelheim International GmbH $49.88 02/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664268
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 02/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664270
Principal investigator 1 Boehringer Ingelheim International GmbH $69.96 01/27/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664286
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 01/27/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664288
Principal investigator 1 Boehringer Ingelheim International GmbH $146.00 01/27/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664290
Principal investigator 1 Eisai Inc. $4,898.70 01/23/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244557707
Principal investigator 1 Eisai Inc. $11,490.25 01/21/2025 Non-covered Recipient Entity
ERG HOLDING COMPANY DBA ST LOUIS CLINICAL TRIALS
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 1244558682
Principal investigator 1 Eli Lilly and Company $1,113.00 01/21/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187874855
Principal investigator 1 ABBVIE INC. $1,750.00 01/03/2025 Non-covered Recipient Entity
BIO BEHAVIORAL HEALTH
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202436542
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664250
Principal investigator 1 Boehringer Ingelheim International GmbH $45.00 01/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664252
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664254
Principal investigator 1 Boehringer Ingelheim International GmbH $30.00 01/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664256
Principal investigator 1 Boehringer Ingelheim International GmbH $73.39 01/01/2025 Non-covered Recipient Entity
Bio-Behavioral Health
A 6-week, multi-centre, randomised, double-blind (participant and investigator), placebo-controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 in patients with major depressive disorder No dispute reported 06/30/2026 1220664298